PPARγ disease gene network and identification of therapeutic targets for prostate cancer

References

• Altenberg B, Greulich KO. (2004). Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics, 84, 1014–1020.
   PubMed Web of Science ®Google Scholar
• Aronowski J. (2002). Peroxisome proliferator-activated receptor-reduces damage produced by focal ischemia. Abstr-Soc Neurosci, Program No. 389.6.
   Google Scholar
• Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM. (1999). PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell, 4, 585–595.
   PubMed Web of Science ®Google Scholar
• Bernhagen J, Bacher M, Calandra T, Metz CN, Doty SB, Donnelly T, Bucala R. (1996). An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med, 183, 277–282.
   PubMed Web of Science ®Google Scholar
• Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR. (1999). Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med, 189, 341–346.
   PubMed Web of Science ®Google Scholar
• Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. (2002). Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson’s disease. J Neurochem, 82, 615–624.
   PubMed Web of Science ®Google Scholar
• Butler R, Mitchell SH, Tindall DJ, Young CY. (2000). Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. Cell Growth Differ, 11, 49–61.
   PubMedGoogle Scholar
• Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hültner L, Heumann D, Männel D, Bucala R, Glauser MP. (2000). Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med, 6, 164–170.
   PubMed Web of Science ®Google Scholar
• Calandra T, Spiegel LA, Metz CN, Bucala R. (1998). Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc Natl Acad Sci USA, 95, 11383–11388.
   PubMed Web of Science ®Google Scholar
• Chang TH, Szabo E. (2000). Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res, 60, 1129–1138.
   PubMed Web of Science ®Google Scholar
• Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, Christmas R, Avila-Campilo I, Creech M, Gross B, Hanspers K, Isserlin R, Kelley R, Killcoyne S, Lotia S, Maere S, Morris J, Ono K, Pavlovic V, Pico AR, Vailaya A, Wang PL, Adler A, Conklin BR, Hood L, Kuiper M, Sander C, Schmulevich I, Schwikowski B, Warner GJ, Ideker T, Bader GD. (2007). Integration of biological networks and gene expression data using Cytoscape. Nat Protoc, 2, 2366–2382.
   PubMed Web of Science ®Google Scholar
• Crooks GE, Hon G, Chandonia JM, Brenner SE. (2004). WebLogo: a sequence logo generator. Genome Res, 14, 1188–1190.
   PubMed Web of Science ®Google Scholar
• Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. (2004). Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem, 88, 494–501.
   PubMed Web of Science ®Google Scholar
• del Vecchio MT, Tripodi SA, Arcuri F, Pergola L, Hako L, Vatti R, Cintorino M. (2000). Macrophage migration inhibitory factor in prostatic adenocarcinoma: correlation with tumor grading and combination endocrine treatment-related changes. Prostate, 45, 51–57.
   PubMed Web of Science ®Google Scholar
• Della Peruta M, Giagulli C, Laudanna C, Scarpa A, Sorio C. (2010). RHOA and PRKCZ control different aspects of cell motility in pancreatic cancer metastatic clones. Mol Cancer, 9, 61.
   PubMedGoogle Scholar
• Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. (2003). DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol, 4, P3.
   PubMed Web of Science ®Google Scholar
• Du P, Feng G, Flatow J, Song J, Holko M, Kibbe WA, Lin SM. (2009). From disease ontology to disease-ontology lite: statistical methods to adapt a general-purpose ontology for the test of gene-ontology associations. Bioinformatics, 25, i63–i68.
   PubMed Web of Science ®Google Scholar
• DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. (1998). The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis, 19, 49–53.
   PubMed Web of Science ®Google Scholar
• Elstner E, Müller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP. (1998). Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA, 95, 8806–8811.
   PubMed Web of Science ®Google Scholar
• Evans RM, Barish GD, Wang YX. (2004). PPARs and the complex journey to obesity. Nat Med, 10, 355–361.
   PubMed Web of Science ®Google Scholar
• Feilchenfeldt J, Bründler MA, Soravia C, Tötsch M, Meier CA. (2004). Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARgamma-coactivator 1 (PGC-1). Cancer Lett, 203, 25–33.
   PubMed Web of Science ®Google Scholar
• Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT. (2002). Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol, 51, 694–702.
   PubMed Web of Science ®Google Scholar
• Fontaine C, Dubois G, Duguay Y, Helledie T, Vu-Dac N, Gervois P, Soncin F, Mandrup S, Fruchart JC, Fruchart-Najib J, Staels B. (2003). The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation. J Biol Chem, 278, 37672–37680.
   PubMed Web of Science ®Google Scholar
• Fukushima M, Sasaki H, Fukushima S. (1994). Prostaglandin J2 and related compounds. Mode of action in G1 arrest and preclinical results. Ann N Y Acad Sci, 744, 161–165.
   PubMed Web of Science ®Google Scholar
• Gaci O. A topological description of hubs in amino acid interaction networks (2010). Adv Bioinform., 257512. (No other details in PubMed)
   PubMedGoogle Scholar
• Gervois P, Chopin-Delannoy S, Fadel A, Dubois G, Kosykh V, Fruchart JC, Najib J, Laudet V, Staels B. (1999). Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element. Mol Endocrinol, 13, 400–409.
   PubMed Web of Science ®Google Scholar
• Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. (1999). Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia, 1, 330–339.
   PubMedGoogle Scholar
• Gupta RA, Brockman JA, Sarraf P, Willson TM, DuBois RN. (2001). Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem, 276, 29681–29687.
   PubMed Web of Science ®Google Scholar
• Han S, Inoue H, Flowers LC, Sidell N. (2003). Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells. Clin Cancer Res, 9, 4627–4635.
   PubMed Web of Science ®Google Scholar
• Han SW, Greene ME, Pitts J, Wada RK, Sidell N. (2001). Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells. Clin Cancer Res, 7, 98–104.
   PubMed Web of Science ®Google Scholar
• Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann DA. (2002). Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab, 87, 772–775.
   PubMed Web of Science ®Google Scholar
• Heneka MT, Landreth GE, Feinstein DL. (2001). Role for peroxisome proliferator-activated receptor-gamma in Alzheimer’s disease. Ann Neurol, 49, 276.
   PubMed Web of Science ®Google Scholar
• Houseknecht KL, Cole BM, Steele PJ. (2002). Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol, 22, 1–23.
   PubMed Web of Science ®Google Scholar
• Hsueh WA, Bruemmer D. (2004). Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension, 43, 297–305.
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. (2003). Cancer statistics. CA Cancer J Clin., 53,1, 5–26.
   PubMed Web of Science ®Google Scholar
• Kamimura A, Kamachi M, Nishihira J, Ogura S, Isobe H, Dosaka-Akita H, Ogata A, Shindoh M, Ohbuchi T, Kawakami Y. (2000). Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer, 89, 334–341.
   PubMed Web of Science ®Google Scholar
• Keshamouni VG, Arenberg DA, Reddy RC, Newstead MJ, Anthwal S, Standiford TJ. (2005). PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia, 7, 294–301.
   PubMed Web of Science ®Google Scholar
• Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A, Balakrishnan L, Marimuthu A, Banerjee S, Somanathan DS, Sebastian A, Rani S, Ray S, Harrys Kishore CJ, Kanth S, Ahmed M, Kashyap MK, Mohmood R, Ramachandra YL, Krishna V, Rahiman BA, Mohan S, Ranganathan P, Ramabadran S, Chaerkady R, Pandey A. (2009). Human Protein Reference Database—2009 update. Nucleic Acids Res, 37, D767–D772.
   PubMed Web of Science ®Google Scholar
• Kim IK, Lee JH, Sohn HW, Kim HS, Kim SH. (1993). Prostaglandin A2 and delta 12-prostaglandin J2 induce apoptosis in L1210 cells. FEBS Lett, 321, 209–214.
   PubMed Web of Science ®Google Scholar
• Krentz AJ, Friedmann PS. (2006). Type 2 diabetes, psoriasis and thiazolidinediones. Int J Clin Pract, 60, 362–363.
   PubMed Web of Science ®Google Scholar
• Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP. (1998). Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res, 58, 3344–3352.
   PubMed Web of Science ®Google Scholar
• Kumar AP, Quake AL, Chang MKX, Lim KSY, Eng CB, Singh R, Hewitt RE, Salto-Tellez M, Pervaiz S, Clement MV. (2009). Repression of the Na+/H+ exchanger 1 expression by PPARg activation is a potential new approach for specific inhibition of tumor cells’ growth in vitro and in vivo. Cancer Res., 69, 22, 8636–8644.
   Google Scholar
• Kumar AP, Piedrafita FJ, Reynolds WF. (2004). Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the −463GA promoter polymorphism. J Biol Chem, 279, 8300–8315.
   PubMed Web of Science ®Google Scholar
• Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, Weedon H, Holdsworth SR, Bucala R, Morand EF. (1999). Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum, 42, 1601–1608.
   PubMed Web of Science ®Google Scholar
• Leech M, Metz C, Santos L, Peng T, Holdsworth SR, Bucala R, Morand EF. (1998). Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum, 41, 910–917.
   PubMed Web of Science ®Google Scholar
• Lehrke M, Lazar MA. (2005). The many faces of PPARgamma. Cell, 123, 993–999.
   PubMed Web of Science ®Google Scholar
• Lieberthal W, Menza SA, Levine JS. (1998). Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells. Am J Physiol, 274, F315–F327.
   PubMed Web of Science ®Google Scholar
• Makita H, Nishimura M, Miyamoto K, Nakano T, Tanino Y, Hirokawa J, Nishihira J, Kawakami Y. (1998). Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation. Am J Respir Crit Care Med, 158, 573–579.
   PubMed Web of Science ®Google Scholar
• Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. (1995). The nuclear receptor superfamily: the second decade. Cell, 83, 835–839.
   PubMed Web of Science ®Google Scholar
• Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ. (2004). 2-Deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res, 64, 31–34.
   PubMed Web of Science ®Google Scholar
• Mikulowska A, Metz CN, Bucala R, Holmdahl R. (1997). Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol, 158, 5514–5517.
   PubMed Web of Science ®Google Scholar
• Mössner R, Schulz U, Krüger U, Middel P, Schinner S, Füzesi L, Neumann C, Reich K. (2002). Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol, 119, 576–582.
   PubMed Web of Science ®Google Scholar
• Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. (2000). Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res, 60, 5558–5564.
   PubMed Web of Science ®Google Scholar
• Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. (1998). Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell, 1, 465–470.
   PubMed Web of Science ®Google Scholar
• Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. (1998). Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell, 1, 465–470.
   PubMed Web of Science ®Google Scholar
• Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. (2000). Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA, 97, 10990–10995.
   PubMed Web of Science ®Google Scholar
• Nakashiro K, Begum NM, Uchida D, Kawamata H, Shintani S, Sato M, Hamakawa H. (2003). Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma. Oral Oncol, 39, 855–861.
   PubMed Web of Science ®Google Scholar
• Nielsen R, Pedersen TA, Hagenbeek D, Moulos P, Siersbaek R, Megens E, Denissov S, Børgesen M, Francoijs KJ, Mandrup S, Stunnenberg HG. (2008). Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev, 22, 2953–2967.
   PubMed Web of Science ®Google Scholar
• Niino M, Iwabuchi K, Kikuchi S, Ato M, Morohashi T, Ogata A, Tashiro K, Onoé K. (2001). Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J Neuroimmunol, 116, 40–48.
   PubMed Web of Science ®Google Scholar
• Nijsten T, Geluyckens E, Colpaert C, Lambert J. (2005). Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors. J Cutan Pathol, 32, 340–347.
   PubMed Web of Science ®Google Scholar
• Ondrey F. (2009). Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res, 15, 2–8.
   PubMed Web of Science ®Google Scholar
• Osborne JD, Flatow J, Holko M, Lin SM, Kibbe WA, Zhu LJ, Danila MI, Feng G, Chisholm RL. (2009). Annotating the human genome with disease ontology. BMC Genom, 10 (Suppl 1), S6.
   PubMedGoogle Scholar
• Panigrahy D, Huang S, Kieran MW, Kaipainen A. (2005). PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther, 4, 687–693.
   PubMed Web of Science ®Google Scholar
• Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. (2001). Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol, 11, 764–768.
   PubMed Web of Science ®Google Scholar
• Rhead B, Karolchik D, Kuhn RM, Hinrichs AS, Zweig AS, Fujita PA, Diekhans M, Smith KE, Rosenbloom KR, Raney BJ, Pohl A, Pheasant M, Meyer LR, Learned K, Hsu F, Hillman-Jackson J, Harte RA, Giardine B, Dreszer TR, Clawson H, Barber GP, Haussler D, Kent WJ. (2010). The UCSC Genome Browser database: update 2010. Nucleic Acids Res, 38, D613–D619.
   PubMed Web of Science ®Google Scholar
• Rossi AG, Haslett C, Hirani N, Greening AP, Rahman I, Metz CN, Bucala R, Donnelly SC. (1998). Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest, 101, 2869–2874.
   PubMed Web of Science ®Google Scholar
• Sakharkar MK, Sakharkar KR. (2008). Genetic and pharmacological interaction network of targets and drugs. Int J Integ Biol, 4, 1–8.
   Google Scholar
• Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM. (1998). Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med, 4, 1046–1052.
   PubMed Web of Science ®Google Scholar
• Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, Rumi MA, Fukuda R, Nagasue N, Kinoshita Y. (2000). Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer, 83, 1394–1400.
   PubMed Web of Science ®Google Scholar
• Scardoni G, Petterlini M, Laudanna C. (2009). Analyzing biological network parameters with CentiScaPe. Bioinformatics, 25, 2857–2859.
   PubMed Web of Science ®Google Scholar
• Scatena R, Bottoni P, Pontoglio A, Mastrototaro L, Giardina B. (2008). Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investig Drugs, 17, 1533–1545.
   PubMed Web of Science ®Google Scholar
• Shimazu T, Inoue I, Araki N, Asano Y, Sawada M, Furuya D, Nagoya H, Greenberg JH. (2005). A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke, 36, 353–359.
   PubMed Web of Science ®Google Scholar
• Singh RP, Agarwal R. (2006). Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer, 13, 751–778.
   PubMed Web of Science ®Google Scholar
• Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, Schultz PG, Powell SM, Moskaluk CA, Frierson HF Jr, Hampton GM. (2001). Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res, 61, 7388–7393.
   PubMed Web of Science ®Google Scholar
• Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. (2005). Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience, 130, 685–696.
   PubMed Web of Science ®Google Scholar
• Theocharis S, Kanelli H, Politi E, Margeli A, Karkandaris C, Philippides T, Koutselinis A. (2002). Expression of peroxisome proliferator activated receptor-gamma in non-small cell lung carcinoma: correlation with histological type and grade. Lung Cancer, 36,3, 249–255.
   PubMed Web of Science ®Google Scholar
• Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, Diemer K, Muruganujan A, Narechania A. (2003). PANTHER: a library of protein families and subfamilies indexed by function. Genome Res, 13, 2129–2141.
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, Mueller E, Altiok S, Oppenheim H, Evans RM, Spiegelman BM. (1997). Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA, 94, 237–241.
   PubMed Web of Science ®Google Scholar
• Venkatachalam G, Kumar AP, Yue LS, Pervaiz S, Clement MV, Sakharkar MK. (2009). Computational identification and experimental validation of PPRE motifs in NHE1 and MnSOD genes of human. BMC Genomics, 10 (Suppl 3), S5.
   PubMedGoogle Scholar
• Venkatachalam G, Sakharkar MK, Kumar AP, Clement MV. (2009). PPRESearch: Peroxisome Proliferator Activator Element Search Database. Int J Integ Biol, 8, 37–42.
   Google Scholar
• Wang J, Wang J, Dai J, Jung Y, Wei CL, Wang Y, Havens AM, Hogg PJ, Keller ET, Pienta KJ, Nor JE, Wang CY, Taichman RS. (2007). A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res, 67, 149–159.
   PubMed Web of Science ®Google Scholar
• Warburg O, Posener K, Negelein E. (1924). Ueber den Stoffwechsel der Tumoren. Biochemische Zeitschrift, 152, 319–344.
   Google Scholar
• Watson GS, Craft S. (2003). The role of insulin resistance in the pathogenesis of Alzheimer’s disease: implications for treatment. CNS Drugs, 17, 27–45.
   PubMed Web of Science ®Google Scholar